Arbutus Biopharma
ABUS
122 hedge funds and large institutions have $189M invested in Arbutus Biopharma in 2023 Q1 according to their latest regulatory filings, with 20 funds opening new positions, 37 increasing their positions, 31 reducing their positions, and 11 closing their positions.
327% more call options, than puts
Call options by funds: $5.24M | Put options by funds: $1.23M
82% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 11
50% more capital invested
Capital invested by funds: $126M → $189M (+$63M)
19% more repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 31
7% more funds holding
Funds holding: 114 → 122 (+8)
3.79% more ownership
Funds ownership: 34.64% → 38.44% (+3.8%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$13.1M |
| 2 |
WCM
Whitefort Capital Management
New York
|
+$10.3M |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
+$7.5M |
| 4 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$2.06M |
| 5 |
KCM
Kennedy Capital Management
St Louis,
Missouri
|
+$1.11M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
-$5.97M |
| 2 |
OMC
Oasis Management Company
Grand Cayman,
Cayman Islands
|
-$2.54M |
| 3 |
EMG
ETF Managers Group
Summit,
New Jersey
|
-$1.66M |
| 4 |
BlackRock
New York
|
-$667K |
| 5 |
Millennium Management
New York
|
-$542K |
ABUS Hedge Fund Activity: Q1 2023 in Review
122 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in Arbutus Biopharma (ABUS) for Q1 2023, worth a combined $189M — up 50% from $126M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new ABUS positions and 11 closed out — a net gain of 9 holders — while 37 added to existing stakes and 31 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $13.1M. The largest seller was Hudson Bay Capital Management, cutting an estimated $5.97M.
- 122 institutional investors held Arbutus Biopharma (ABUS) as of Q1 2023, up from 114 in Q4 2022.
- Funds reported $189M of Arbutus Biopharma stock for Q1 2023, up 50% quarter-over-quarter.
- 20 funds opened new Arbutus Biopharma positions in Q1 2023 and 11 closed out, a net change of +9 holders.
- The largest Arbutus Biopharma buyer in Q1 2023 was Morgan Stanley, an estimated $13.1M added.
- The largest Arbutus Biopharma seller in Q1 2023 was Hudson Bay Capital Management, an estimated $5.97M sold.
Based on aggregated 13F filings for Q1 2023.